Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...

In the same year, it also created the Novartis Institutes for BioMedical Research (NIBR), which headquarters in the US. In 2003, Novartis acquired the worldwide adult medical nutrition business of ...

Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D executive ...

Feb 11 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's (BX.N), opens new tab drug ...

Novartis Institutes for Biomedical Research, Inc., ("Novartis") has entered into a fully paid up license agreement of Housey Pharma's core-enabling technologies for new-drug discovery with HMI ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost ...

Return on investment - most recent fiscal year 10.71 ...

Novartis will acquire Anthos Therapeutics for $925M upfront. The deal is expected to close in H1 2025. Anthos’ abelacimab showed reduced bleeding risks in Phase 2 trials and is in three Phase 3 ...

Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...